Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone

This study has been completed.
FNRS (Belgium)
Information provided by:
Université Catholique de Louvain Identifier:
First received: March 20, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted
18 F-fluoride Positron emission tomography (PET) is able to demonstrate and quantify the metabolic activity locally in the skeleton (1). This technique should, therefore, also be able to demonstrate a dramatic decrease in the metabolic activity in localized monostotic Paget’s disease lesions after therapy. In this condition, indeed, the usual biological markers may be unhelpful to assess the efficacy of therapy, because they are usually comprised in the normal range for single pagetic localizations, even before therapy (2). The main purpose of this trial is to assess the early and long term response of pagetic bone to bisphosphonate therapy.

Condition Intervention
Paget's Disease of Bone
Drug: Bisphosphonate treatment

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of 18F-Fluoride Positron Emission Tomography in the Assessment and Evaluation of Therapy in Monostotic Paget's Disease of Bone

Resource links provided by NLM:

Further study details as provided by Université Catholique de Louvain:

Estimated Enrollment: 20
Study Start Date: February 2002
Estimated Study Completion Date: March 2006
  Show Detailed Description


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a monostotic form of PDB (as attested by plain X-rays and 99mTc MDP bone scintigraphy)
  • Bone pain linked to Paget’s disease itself

Exclusion Criteria:

  • Bisphosphonate therapy within the year prior to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00306046

Rheumatology, Molecular Imaging and Experimental Radiotherapy departments, Saint-Luc University Hospital, Catholic University of Louvain
Brussels, Belgium, 1200
Sponsors and Collaborators
Université Catholique de Louvain
FNRS (Belgium)
Principal Investigator: Adrien T. NZEUSSEU, MD Université Catholique de Louvain
Principal Investigator: Max LONNEUX, MD, PhD Université Catholique de Louvain
Principal Investigator: Johanne INSTALLE, MD Université Catholique de Louvain
Principal Investigator: Anne BOL, PhD Université Catholique de Louvain
Principal Investigator: Geneviève DEPRESSEUX Université Catholique de Louvain
Study Director: Jean-Pierre DEVOGELAER, MD Université Catholique de Louvain
  More Information

Publications: Identifier: NCT00306046     History of Changes
Other Study ID Numbers: 3.4528.03 F
Study First Received: March 20, 2006
Last Updated: March 20, 2006

Keywords provided by Université Catholique de Louvain:
Positron-Emission Tomography
Biochemical Markers
Paget's Disease of Bone (monostotic and polyostotic)

Additional relevant MeSH terms:
Bone Diseases
Osteitis Deformans
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs
Cariostatic Agents
Protective Agents processed this record on May 22, 2017